Replies to post #164497 on Biotech Values

[oc631]

GILD expects GT3 labeling to be the focus of Sofosbuvir's FDA advisory panel on 10/25/13, according to today's CC.

The cost to the healthcare system for retreating patients would be huge if Sofo/Riba is labeled for GT3. This should be a fun advisory panel.


I didn't get to listen to the call yet. What stands out in the PR is how well the sofosbuvir/ledipasvir combo is working without riba.